

August 30, 2018



## Synthetic Biologics to Present at the 20th Annual Rodman & Renshaw Global Investment Conference

ROCKVILLE, Md., Aug. 30, 2018 /PRNewswire/ -- [Synthetic Biologics, Inc.](http://www.syntheticbiologics.com) (NYSE American: SYN), a late-stage clinical company developing therapeutics that preserve the microbiome to protect and restore the health of patients, announced today that Steven A. Shallcross, Interim Chief Executive Officer & Chief Financial Officer, will present a corporate overview at the 20<sup>th</sup> Annual Rodman & Renshaw Global Investment Conference, sponsored by H.C. Wainwright & Co., LLC, in New York City on Thursday, September 6, 2018, at 9:35 a.m. ET.



A live webcast of Synthetic Biologics' presentation may be accessed by logging onto the web at <http://www.syntheticbiologics.com/webcast/rrshq28/syn/>. After the presentation, a replay will be archived and accessible for 60 days on Synthetic Biologics' website, [www.syntheticbiologics.com](http://www.syntheticbiologics.com).

### About Synthetic Biologics, Inc.

Synthetic Biologics, Inc. (NYSE American: SYN) is a late-stage clinical company developing therapeutics that preserve the microbiome to protect and restore the health of patients. The Company's lead candidates poised for Phase 3 development are: (1) SYN-004 (ribaxamase) which is designed to protect the gut microbiome from the effects of certain commonly used intravenous (IV) beta-lactam antibiotics for the prevention of *C. difficile* infection (CDI), overgrowth of pathogenic organisms and the emergence of antimicrobial resistance (AMR), and (2) SYN-010 which is intended to reduce the impact of methane producing organisms in the gut microbiome to treat an underlying cause of irritable bowel syndrome with constipation (IBS-C). The Company's preclinical pursuits include an oral formulation of the enzyme intestinal alkaline phosphatase (IAP) to treat both local GI and systemic diseases as well as monoclonal antibody therapies for the prevention and treatment of pertussis, and novel discovery stage biotherapeutics for the treatment of phenylketonuria (PKU). For more information, please visit Synthetic Biologics' website at [www.syntheticbiologics.com](http://www.syntheticbiologics.com).

View original content with multimedia <http://www.prnewswire.com/news-releases/synthetic-biologics-to-present-at-the-20th-annual-rodman--renshaw-global-investment-conference-300704898.html>

SOURCE Synthetic Biologics, Inc.